Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine clinical trials
Also written PRGN-2009.
How each study uses Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PRGN-2009
- 3
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
National Cancer Institute (NCI) (3) · Precigen, Inc (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine.
- Nov 2026PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerPhase 2 · Precigen, Inc
Studies
Open first, then newest update. How each study uses Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06223568Written as PRGN-2009How we know
- PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical CancerRecruitingPhase 2Precigen, IncNCT06157151Written as PRGN-2009 plus PembrolizumabHow we know
- HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT04432597Written as PRGN-2009How we know
- Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05996523Written as PRGN-2009How we know